Literature DB >> 18752463

Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil.

Maria Cássia Mendes-Correa1, Azzo Widman, Maria Luiza Paes Brussi, Cristina Fátima Guastini, Reinaldo José Gianini.   

Abstract

The aim of this study was to examine the incidence and factors associated with the severity of liver fibrosis in 234 coinfected patients in Brazil. Patients were cared for in our clinic, from 1996 to 2004. Eligible patients were defined as patients with documented HIV and hepatitis C virus (HCV) infections and had previously undergone a liver biopsy. Patients with persistently normal alanine aminotransferase (ALT) were also included. The variables selected for study were age, gender, risk category, history of high alcohol consumption, CD4(+) T cell count, antiretroviral therapy usage, HCV genotype and duration of HCV infection. Stage of fibrosis was scored as follows: F0, no fibrosis; F1, portal fibrosis with no septa; F2, portal fibrosis with few septa; F3, bridging fibrosis with many septa; and F4, cirrhosis. The liver fibrosis stage was F3 in 39 (16.6%) and F4 in 20(8.5%) patients. Among patients with normal ALT, the liver fibrosis stage was F3-F4 in three patients (5.6%). Predictors of severe liver fibrosis (F3-F4) by multivariate analysis were age (older patients) and genotype 3 (genotype 1 = odds ratio [OR], 0.28; 95% confidence interval [CI], 0.12 0.65). In summary, in the present study severe liver fibrosis was found in 25% of our patients and was associated with an age of more than 38 years at the time of liver biopsy as well as, HCV genotype 3. No differences were found with respect to CD4(+) T cell counts although patients with a CD4(+) T cell count greater than 50 were excluded.

Entities:  

Mesh:

Year:  2008        PMID: 18752463     DOI: 10.1089/apc.2007.0216

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  4 in total

1.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

2.  Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection.

Authors:  Anu Osinusi; David Kleiner; Brad Wood; Michael Polis; Henry Masur; Shyam Kottilil
Journal:  AIDS Patient Care STDS       Date:  2009-06       Impact factor: 5.078

3.  CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug users.

Authors:  Jeffrey P Anderson; C Robert Horsburgh; Paige L Williams; Eric J Tchetgen Tchetgen; David Nunes; Deborah Cotton; George R Seage
Journal:  Open Forum Infect Dis       Date:  2015-02-28       Impact factor: 3.835

4.  Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis.

Authors:  Hang Lyu; Haotong Tang; Yizhi Liang; Shaoli Huang; Yuyu Wang; Wenyan Huang; Yi Zhou
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.